Safety and Immunogenicity of rBCG-N-hRSV Vaccine in Healthy Males

Phase 1, randomised, double-blind trial of rBCG-N-RSV vaccine in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Pontificia Universidad Católica de Chile. Primary endpoint: Number of Subjects With Required Adverse Events Grade II, III, and IV, Laboratory Adverse Events Grade II, III, and IV, and Severe Considered Adverse Events Related to the Vaccine up to 180 days. Started Jun 2017; status: completed.